TMCnet

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in ...
TipRanks on MSN

OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe

OSR Holdings (OSRH) announced that Vaximm AG, an OSR company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life ...

OSR Holdings stock soars after Vaximm enters licensing term sheet

Investing.com -- OSR Holdings Inc (NASDAQ:OSRH) stock surged 30.5% on Friday after the company announced its subsidiary Vaximm AG had entered a non-binding term sheet with BCM Europe AG to explore a ...

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief ...

Head and Neck Cancer Drugs/Therapeutics Market Backed by Growing Adoption of Immunotherapy, Advancements in Targeted Treatment Approaches - Market Resear…

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and ...
WDAF-TV

Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Martinsried/Munich, April 27, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Times Union

Novartis AG (ADR) Boosts its Cancer Immunotherapy Presence

Despite outstanding performance over the past year from biotech and pharma, you wouldn't be alone if you think they have more room to grow. In a recent survey of over 200 buy-side health care ...